Drug intelligence / Profile preview

MUC1-KLH + QS-21 (Memorial Sloan Kettering Cancer Center)

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Vaccines & Immunotherapeutics, Peptides
Administration: Subcutaneous

Overview

MUC1-KLH + QS-21 is a therapeutic cancer vaccine composed of a glycosylated MUC-1 peptide conjugated to the carrier protein keyhole limpet hemocyanin (KLH) and formulated with the immunological adjuvant QS-21. Developed by Memorial Sloan Kettering Cancer Center, the vaccine is designed to induce an immune response against Mucin-1 (MUC-1), a glycoprotein that is overexpressed and aberrantly glycosylated in various epithelial cancers. The inclusion of the KLH carrier and the saponin-based adjuvant QS-21 is intended to enhance the immunogenicity of the MUC-1 antigen and overcome immune tolerance. It has been evaluated in Phase I clinical trials for the treatment of refractory or recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cavity cancer.

Other names: MUC1-KLH vaccine/QS21glycosylated MUC-1-KLH conjugate plus QS-21MUC1-KLH conjugate vaccineMUC-1-KLH conjugate vaccineMUC 1-KLH conjugate vaccineMUC-1-KLH vaccine + QS-21

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on MUC1-KLH + QS-21 (Memorial Sloan Kettering Cancer Center).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUC1-KLH + QS-21 (Memorial Sloan Kettering Cancer Center).